Klotho Neurosciences (NASDAQ:KLTO) has appointed Makoto Kuro-o, MD, Ph.D., to its scientific advisory board.
Dr. Kuro-o, a pioneer in the discovery of the anti-aging Klotho (s-KL) gene, will support Klotho’s mission to develop therapies targeting the biological mechanisms of aging and improving treatments for neurodegenerative diseases.
In a statement, Klotho Neurosciences CEO, Dr. Joseph Sinkule said, “Dr. Kuro-o’s discovery of the Klotho gene revolutionized our understanding of the biology of aging. His insights will be invaluable as we work to develop our patent-protected secreted form of s-KL as a treatment for neurodegenerative diseases, including ALS, Alzheimer’s, and Parkinson’s disease. We are confident that his involvement will significantly accelerate our efforts to bring s-KL-based therapies to clinical trials and ultimately to patients.”
In response to his appointment, Dr. Kuro-o said, “I am honored to join the scientific advisory board at Klotho Neurosciences. The innovative work being done with s-KL, the company’s patented secreted form of Klotho, is truly impressive. I am excited to collaborate with the other members of the scientific advisory board to advance this promising therapeutic approach.”
